HIV
From the Journals
Opt-out policy at a syringe service program increased HIV/HCV testing
For HIV and HCV among people who inject drugs, it is important to improve diagnosis and linkage to care.
Conference Coverage
Aging with HIV adds to comorbidity burden
From the Journals
HIV drugs prevent type 2 diabetes, may be path to new therapy
Conference Coverage
Acute HIV cases double in ED. Is COVID-19 responsible?
“The reason testing is so important, whether for HIV or COVID, is the more you test, the more you’re going to find.”
Conference Coverage
TDF preferred in PrEP for Blacks and women, studies indicate
Conference Coverage
Shared decision-making aids choice of PrEP
Conference Coverage
Four-week, 8-week CAB/RPV injections safe, effective in women
At 48 weeks, 3.6% of women in the 8-week group had at least 50 copies/mL of HIV-1 RNA.
From the Journals
Social factors predicted peripartum depressive symptoms in Black women with HIV
Those factors included having low income and experiencing intimate partner violence.
Conference Coverage
Heterosexual men likely to have unmet HIV treatment needs
In high-income countries, men with HIV who had sex with men were diagnosed earlier than men with HIV who had sex with women.
From the Journals
Dual therapy serves as well as triple for most HIV patients
Patients with a low viral load were significantly more likely to experience treatment failure on dual therapy than on triple therapy.
Conference Coverage
Being HIV positive increases risk of death from COVID-19
For patients below the age of 70, the risk of mortality was double in people with HIV.